MAP2K7 and breast cancer: Furthermore we looked at in-vitro sensitivity to the MEK inhibitors which are currently under clinical evaluation in triple negative breast cancer and found that 10/15 triple negative cells analysed were sensitive to MEK inhibitors (PD-0325901 and trametinib) we also observed that 12/17 HER2-positve breast cancer cells lines were also sensitive (Supplementary Table 3).